DEVLAB

H1 FY27 Standalone Revenue ₹34.33Cr vs ₹49.24Cr (▼30% YoY) EBITDA ₹0.90Cr vs ₹0.97Cr (▼7% YoY) PAT ₹0.12Cr vs ₹0.34Cr (▼63% YoY) EBITDA Margin 2.6% vs 2.0% (▲60bps)

H1 FY27 Consolidated Revenue ₹155.17 Cr vs ₹49.24 Cr (▲215% YoY) EBITDA ₹9.82 Cr vs ₹0.97 Cr (▲914% YoY) PAT ₹9.04 Cr vs ₹0.34 Cr (▲2585% YoY) EBITDA Margin 6.33% vs 1.97% (▲436bps)

Dev Labtech Venture Ltd announced the issuance of up to 1,37,00,000 convertible warrants. - The issue is on a preferential basis to promoters/promoter group and non-promoters. - The total issue size is Rs. 17.81 crores at Rs. 13/- per warrant (Face Value Rs. 5/-, Premium Rs. 8/-). - The EGM approving the fundraising was held on 5th November 2026.

- Dev Labtech Venture Ltd held its Extraordinary General Meeting (EGM) on November 5, 2026. - Shareholders approved increasing the authorized share capital and amending the Memorandum of Association. - Shareholders approved the issuance of convertible warrants on a preferential issue basis.

- Dev Labtech Venture Limited held its Extra Ordinary General Meeting (EGM) on November 5, 2026, through Video Conferencing. - Shareholders considered and voted on increasing the authorized share capital and amending the Memorandum of Association. - Approval was sought to issue convertible warrants on a preferential issue basis.

- Board meeting scheduled for November 6, 2026. - To consider and approve Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026. - Trading window remains closed until 48 hours post result declaration.

- Dev Labtech Venture Limited has announced an Extra Ordinary General Meeting (EGM) scheduled for Thursday, 5th November, 2026 at 1:00 p.m. through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). - The meeting will consider increasing the Authorised Share Capital from ₹25,00,00,000 to ₹31,00,00,000 and amending the Memorandum of Association. - It includes a proposal to issue up to 1,37,00,000 Convertible Warrants on a preferential basis at ₹13 each, aggregating ₹17,81,00,000 to promoter and non-promoter allottees.

- Dev Labtech Venture Ltd announced an increase in its authorized share capital from ₹25 crores to ₹31 crores. - Board approved the issuance of up to 1,37,00,000 convertible warrants at ₹13 each on a preferential basis, aggregating to ₹17.81 crores. - An Extra Ordinary General Meeting (EGM) is scheduled for November 5, 2026, with a cut-off date of October 29, 2026.

- The Board of Directors approved increasing the Authorized Share Capital from ₹25 Crore to ₹31 Crore. - Approved issuing up to 1,37,00,000 convertible warrants at ₹13 each on a preferential basis, aggregating to ₹17.81 Crore. - Convened an Extra Ordinary General Meeting (EGM) on November 5, 2026, with a cut-off date of October 29, 2026.

- Board approved increasing authorized share capital from ₹25 crores to ₹31 crores by altering the Memorandum of Association. - Approved issuing up to 1,37,00,000 convertible warrants at ₹13 each (face value ₹5, premium ₹8) on a preferential basis, aggregating to ₹17.81 crores to promoters and non-promoters. - Fixed EGM date for 5th November, 2026, with a cut-off date of 29th October, 2026, for voting.

- Dev Labtech Venture Ltd announced a board meeting outcome on October 7, 2026. - Approved increasing Authorized Share Capital from ₹25 Crore to ₹31 Crore. - Approved issuing up to 1,37,00,000 convertible warrants at ₹13 each on a preferential basis, aggregating to ₹17.81 Crore. - Scheduled an Extra Ordinary General Meeting (EGM) on November 5, 2026.